ROCURONIUM KABI 10 mg/ml INJECTABLE SOLUTION AND PERFUSION SOLUTION

2. What you need to know before you use Rocuronio Kabi

Do not use Rocuronio Kabi

• If you are allergic to rocuronium bromide, bromide ion or any of the other components of this medicine (listed in section 6).

Components of this medicine (listed in section 6).

Warnings and precautions

Tell your doctor, pharmacist or nurse before starting treatment with Rocuronio Kabi if any of the following conditions apply to you or have applied in the past:

• If you are allergic to other muscle relaxants
• If you have kidney, liver or gallbladder disease
• If you have heart disease or a disease that affects blood circulation
• If you have edema (e.g. in the ankle area)
• If you have a disease that affects the nerves and muscles (neuromuscular diseases, e.g. polio (poliomyelitis), myasthenia gravis, Eaton-Lambert syndrome)

Diseases that affect the nerves and muscles (neuromuscular diseases, e.g. polio (poliomyelitis), myasthenia gravis, Eaton-Lambert syndrome)

• If you have ever developed a body temperature that is too low during anesthesia (hypothermia)
• If you have a history of malignant hyperthermia (sudden fever with rapid heart rate, rapid breathing and stiffness, pain and/or weakness in the muscles)
• If you have a fever
• If you have low calcium levels in your blood (hypocalcemia), (caused for example by massive transfusions)
• If you have low potassium levels in your blood (hypokalemia), (caused for example by severe vomiting, diarrhea and diuretic therapy)
• If you have high magnesium levels in your blood (hypermagnesemia)
• If you have low protein levels in your blood (hypoproteinemia)
• If you are dehydrated
• If you have an increase in acid levels in your blood (acidosis)
• If you have an increase in carbon dioxide levels in your blood (hypercapnia)
• If you are suffering from excessive weight loss (cachexia)
• If you are obese or elderly
• If you have burns

Using Rocuronio Kabi with other medicines

Tell your doctor or pharmacist if you are using or have recently used other medicines, such as:

• Antibiotics
• Antidepressants: medicines used to treat depression (e.g. lithium salts, MAO inhibitors)
• Medicines used to treat heart diseases or high blood pressure (e.g. quinidine, calcium channel blockers, adrenergic blockers (e.g. beta blockers)
• Diuretics (medicines that increase urine production)
• Certain laxatives such as magnesium salts
• Quinine (used to treat pain and infections)
• Medicines used to treat epilepsy (e.g. phenytoin, carbamazepine)
• Corticosteroids
• Medicines used to treat myasthenia gravis (neostigmine, pyridostigmine)
• Azathioprine (used for the prevention of transplant rejection and the treatment of autoimmune diseases)

Autoimmune diseases)

• Medicines used to treat or prevent viral infections (protease inhibitors: gabexate, ulinastatin)

To be considered:

You may be given other medicines during the procedure that may affect the effects of rocuronium. These include certain anesthetics (e.g. local anesthetics, inhalation anesthetics) and other muscle relaxants. Your doctor will take this into account when deciding the correct dose of rocuronium for you.

Pregnancy and breastfeeding

If you are pregnant or breastfeeding, think you may be pregnant or are planning to have a baby, ask your doctor, pharmacist or nurse for advice before using this medicine.

There are no clinical data on the use of Rocuronio Kabi during pregnancy and breastfeeding.

Rocuronio Kabi should be administered to pregnant or breastfeeding women only when the doctor decides that the benefits outweigh the risks. Rocuronio Kabi can be used during cesarean section.

Breastfeeding should be discontinued 6 hours after the use of this medicine.

Driving and using machines

Rocuronio Kabi has a major influence on the ability to drive and use machines.

Therefore, it is not recommended to drive a car or use potentially dangerous machines during the first 24 hours.

Your doctor should advise you on when to start driving or using machines again. After treatment, you should always be accompanied home by a responsible adult.

Rocuronio Kabi contains sodium

This medicine contains 3.3 mg of sodium (main component of table salt) per ml. This is equivalent to 0.17% of the maximum recommended daily intake of sodium for an adult.

3. How to use Rocuronio Kabi

Your anesthetist will administer Rocuronio Kabi to you. It will be given to you intravenously as a single injection or as a continuous infusion (over a long period of time) into a vein.

The usual dose is 0.6 mg per kg of body weight and its effect lasts 30-40 minutes. During surgery, the effect of Rocuronio Kabi is continuously monitored.

If necessary, you may be given additional doses. Your anesthetist will adjust the dose according to your needs. It depends on many factors, such as the interaction between medicines (their cross-activity), taking into account the estimated duration of the surgery as well as your age and clinical condition. For pediatric patients and elderly people, the use of Rocuronio Kabi as an adjunct in the intensive care unit is not recommended.

Use in children and adolescents

For neonates (0-27 days), infants and young children (28 days - 23 months), children (2-11 years) and adolescents (12-17 years), the recommended doses are similar to those for adults, except for the speed of continuous infusion in children (2-11 years), which may be higher than in adults. The anesthetist will adapt the infusion rate accordingly.

Experience with rocuronium bromide in a special anesthesia technique called rapid sequence induction is limited in pediatric patients. Therefore, the use of rocuronium bromide for this purpose is not recommended in pediatric patients.

If you receive more Rocuronio Kabi than you should

Your anesthetist will carefully monitor you under medication with Rocuronio Kabi, so it is unlikely that you will be given too much Rocuronio Kabi. If this happens, your anesthetist will ensure that anesthesia and artificial ventilation are continued until you can breathe on your own again.

Other questions

If you have any other questions about the use of this medicine, ask your doctor or pharmacist.

For information intended for healthcare professionals, see the corresponding section later.

4. Possible side effects

Like all medicines, Rocuronio Kabi can cause side effects, although not everybody gets them.

Hypersensitivity reactions (allergic reactions) are very rare but can be life-threatening. A hypersensitivity reaction can include skin rash, itching, difficulty breathing or swallowing in the face, lips, throat or tongue.

Please inform your doctor or nurse immediately if one of these reactions occurs.

Uncommon(may affect up to 1 in 100 people)/ Rare(may affect up to 1 in 1,000 people):

• Pain at the injection site

• The medicine is too effective, not effective enough or is ineffective.
• The medicine works for longer than expected (prolongation of neuromuscular blockade)
• The medicine prolongs anesthesia (delays recovery from anesthesia)
• Decrease in blood pressure (hypotension)
• Increased heart rate (tachycardia)

Very rare(may affect up to 1 in 10,000 people):

• Increased histamine levels in the blood (mediator of allergic reactions)
• Difficulty breathing (bronchospasm)
• Rash, itching
• Flushing
• Facial swelling (facial edema)
• Severe and widespread skin rash (exanthema, erythematous rash)
• Muscle weakness (myopathy)
• Swelling (angioedema)
• Hives
• Loss of movement (flaccid paralysis)
• Circulatory failure (circulatory collapse and shock)
• Difficulty breathing (respiratory failure, apnea)

Unknown

• Respiratory failure
• Stopping breathing (apnea)
• Severe allergic coronary artery spasm (Kounis syndrome) that can cause chest pain (angina) or a heart attack (myocardial infarction)
• Dilated pupils (mydriasis) or fixed pupils that do not change size with light or other stimuli

Pediatric patients:

In clinical studies with pediatric patients treated with rocuronium bromide, the adverse effect of increased heart rate occurred in 1 in 10 people.

Reporting of side effects

If you experience any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. You can also report side effects directly to the Spanish Medicines Agency's website: https://www.notificaram.es. By reporting side effects, you can help provide more information on the safety of this medicine.

5. Conservation of Rocuronio Kabi

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the carton after EXP.

The expiry date is the last day of the month indicated.

Unopened vial: This medicine does not require any special storage conditions.

The medicine should be used immediately after opening the vial.

Do not use this medicine if you notice that the solution is not transparent or free of particles.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and further information

Composition of Rocuronio Kabi

The active substance is rocuronium bromide

Each ml contains 10 mg of rocuronium bromide.

Each 5 ml vial contains 50 mg of rocuronium bromide.

Each 10 ml vial contains 100 mg of rocuronium bromide.

The other ingredients are sodium acetate, sodium chloride, sodium hydroxide, hydrochloric acid and water for injections.

Appearance of the product and pack contents

Rocuronio Kabi is a clear, colorless or pale yellow-brown solution for injection or infusion.

Formats:

Rocuronio Kabi is available in packs of 5 or 10 vials with 5 ml or 10 ml of solution.

Not all pack sizes may be marketed.

Marketing authorization holder and manufacturer

Marketing authorization holder:

Fresenius Kabi España S.A.U.

Marina 16-18

08005 Barcelona

Spain

Manufacturer:

Fresenius Kabi Austria GmbH

Hafnerstraße 36

8055 Graz

Austria

This medicine is authorized in the Member States of the European Economic Areaand the United Kingdom (Northern Ireland) under the following names:

Date of last revision of this leaflet: January 2024

Detailed and up-to-date information on this medicine is available on the website of the Spanish Agency for Medicines and Health Products (AEMPS) http://www.aemps.gob.es

-----------------------------------------------------------------------------------------------------------------

This information is intended only for healthcare professionals:

For single use only.

Unused solutions should be discarded.

The medicine should be used immediately after opening the vial.

After dilution: The physical and chemical stability of the diluted product has been demonstrated for 72 hours at a temperature of up to 30°C.

From a microbiological point of view, the product should be used immediately. If not used immediately, the storage times and conditions prior to use are the responsibility of the user and should not exceed 24 hours at 2-8°C, unless the dilution has been carried out under validated aseptic conditions.

Rocuronio Kabi has been shown to be compatible with: sodium chloride 9 mg/ml (0.9%), glucose 50 mg/ml (5%), glucose 5 mg/ml (5%) in sodium chloride 9 mg/ml (0.9%), Ringer's lactate solution and sterile water for injections.

If Rocuronio Kabi is administered through the same infusion line as other medicines, it is important to flush the infusion line properly (e.g. with sodium chloride 9 mg/ml (0.9%)) between the administration of rocuronium bromide and other medicines for which incompatibility with rocuronium bromide has been demonstrated or for which compatibility with rocuronium bromide has not been demonstrated.

The medicine should not be mixed with other medicines except those mentioned above.

Physical incompatibility has been documented for Rocuronio Kabi when added to solutions containing the following active substances: amphotericin, amoxicillin, azathioprine, cefazolin, cloxacillin, dexamethasone, diazepam, enoximone, erythromycin, famotidine, furosemide, sodium hydrocortisone succinate, insulin, lipid emulsion, methohexital, methylprednisolone, sodium prednisolone succinate, thiopental, trimethoprim and vancomycin.